医学临床研究
   Apr. 6, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2022, Vol. 39 Issue (9): 1315-1317    DOI: 10.3969/j.issn.1671-7171.2022.09.010
Original Articles Current Issue | Archive | Adv Search |
Sequential Treatment of Adult APL Patients with All Trans Retinoic Acid Combined with Arsenic
SHI Rui, WEN Jing, WU Wen, et al
Xi'an Central Hospital and Xi'an Institute of Hematology,Xi'an Shaanxi 710004
Download: PDF (1238 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】To investigate the efficacy of all trans retinoic acid (ATRA) combined with arsenic in sequential treatment of acute promyelocytic leukemia (APL). 【Methods】 The clinical data of 94 APL patients admitted to our hospital were retrospectively analyzed. They were divided into observation group and control group according to different treatment methods, with 47 cases in each group. The control group was treated with ATRA, and the observation group was treated with arsenic based sequential therapy on the basis of the control group. Complete remission (CR) rate and 1-year cumulative survival rate were compared between the two groups. Time for CR patients to reach CR, PML-RARα. The negative conversion rate, recurrence rate, promyelocyte ratio, total leukocyte count and adverse reactions were compared. 【Results】The number of CR cases obtained and the number of CR cases not obtained in the observation group were 41 (87.23%) and 6 (12.77%) respectively, while the number of CR cases obtained and the number of CR cases not obtained in the control group were 40 (85.11%) and 7 (14.89%) respectively, and there was no significant difference between the two groups (P>0.05). The time for patients in the observation group to reach CR was significantly shorter than that in the control group.PML-RARα in the observation group. The negative conversion rate was higher than that of the control group, and the recurrence rate was significantly lower than that of the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the percentage of promyelocytes and total leukocytes between the two groups before treatment (P>0.05); After treatment, the percentage of promyelocytes and total leukocytes in the two groups were significantly lower than those before treatment (P<0.05), and the percentage of promyelocytes and total leukocytes in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in the 1-year cumulative survival rate between the two groups of CR patients (P>0.05), and there was no significant difference in the total adverse reaction rate between the two groups of CR patients (P>0.05). 【Conclusion】 The sequential treatment of APL patients with ATRA combined with arsenic is satisfactory. PML-RARα. The negative conversion rate is high, the recurrence rate is low, the long-term survival rate is high, and the drug safety of the two treatment methods is high.
Key wordsLeukemia,Promyelocytic,Acute      Tretinoin      Arsenicals      Treatment Outcome     
Received: 23 March 2022     
PACS:  R733.71  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Cite this article:   
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.09.010     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I9/1315
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech